CT-P47/Tocilizumab-anoh:一种托西利祖马布生物类似剂
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Clinical drug investigation
|September 30, 2025
概括
CT-P47 (AVTOZMA®) 是一种与托西利祖马布生物相似的药物,是一种IL-6R抑制剂. 临床研究表明CT-P47对类风湿性关节炎患者有效且安全,为参考药物提供了可比的替代品.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 托西利祖马布是一种已确定的IL-6受体抑制剂,用于炎症性疾病.
- 生物类似药提供了可比的治疗选择,并有可能获得更广泛的可用性.
研究的目的:
- 为了评估CT-P47 (AVTOZMA®),一个生物类似的托西利祖马布,其疗效,安全性和免疫性.
- 评估从参考tocilizumab切换到CT-P47.7的影响.
主要方法:
- 物理化学表征,将CT-P47与cilizumab的参考进行比较.
- 在中度至重度类风湿性关节炎患者中进行的药物动力学可比性研究.
- 临床疗效和安全性评估,包括免疫性和切换分析.
主要成果:
- CT-P47表现出与cilizumab相似的物理化学特性和药物动力学概况.
- 在类风湿性关节炎患者中观察到相当的临床疗效和可比的安全性和免疫性.
- 从参考tocilizumab切换到CT-P47并没有对安全性或疗效产生负面影响.
结论:
- CT-P47是一种临床有效和安全的生物仿制品替代品,可以参考tocilizumab.
- 它为患有类风湿性关节炎和其他已批准的适应症的患者提供了可比的治疗选择.
- 这项研究支持CT-P47用于管理以前用tocilizumab治疗的炎症状况.
更多相关视频
08:09Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
Published on: March 14, 2025
1.6K
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
1.0K
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Bioequivalence studies: Biowaivers
227
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
227
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
